<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01368614</url>
  </required_header>
  <id_info>
    <org_study_id>HRC-1006-AVAPS-AE-MS</org_study_id>
    <nct_id>NCT01368614</nct_id>
  </id_info>
  <brief_title>AVAPS-AE Efficacy Study</brief_title>
  <official_title>Randomized Controlled Trial Evaluating the Feasibility of AVAPS-AE vs. CPAP vs.Bilevel Pressure Support Ventilation in Obesity Hypoventilation Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philips Respironics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philips Respironics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the feasibility of using of the Average Volume
      Assured Pressure Support (AVAPS-AE) mode versus Continuous Positive Airway Pressure (CPAP)
      and bilevel pressure support ventilation (PSV) modes of ventilation in patients diagnosed
      with Obesity Hypoventilation syndrome (OHS).

      The investigators believe the use of the AVAPS-AE mode of ventilation after 6 weeks will
      yield daytime gas exchange values which are equivalent or no worse when compared to using
      CPAP and bilevel PSV modes of ventilation in the OHS population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 12, 2011</start_date>
  <completion_date type="Actual">May 30, 2013</completion_date>
  <primary_completion_date type="Actual">May 30, 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Daytime Partial Pressure of Carbon Dioxide in Arterial Blood (PaCO2)</measure>
    <time_frame>Screening &amp; 6 weeks</time_frame>
    <description>Daytime PaCO2 measurements will be assessed for all randomized patients to each mode of ventilation therapy (AVAPS-AE, bilevel PSV, CPAP) after 6 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Daytime Partial Pressure of Oxygen in Arterial Blood(Pa02)</measure>
    <time_frame>Screening &amp; 6 weeks</time_frame>
    <description>Daytime Pa02 measurements will be assessed for all randomized patients to each mode of ventilation therapy (AVAPS-AE, bilevel PSV, CPAP) after 6 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apnea Hypopnea Index (AHI)</measure>
    <time_frame>Screening &amp; 6 weeks</time_frame>
    <description>The AHI is the number of apneas and hypopneas per hour of sleep. It will be evaluated during the screening sleep study and the 6 week follow up sleep study. AHI less than 5 is considered normal. For an Apnea-Hypopnea Index (or AHI) from 5 to 15 denotes mild sleep apnea. Fifteen to 30 is moderate, while a greater than 30 AHI is considered severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epworth Sleepiness Scale</measure>
    <time_frame>Screening &amp; 6 weeks</time_frame>
    <description>Epworth Sleepiness scale is a measure of daytime sleepiness. It is a series of 8 questions answered on a scale of 0 to 3, 0 being no chance of dozing and 3 being a high chance of dozing. The range of the scale is 0 to 24. The higher the total score, the higher the chance of falling asleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe Respiratory Insufficiency Questionnaire (SRIQ)</measure>
    <time_frame>Screening &amp; 6 weeks</time_frame>
    <description>The SRIQ is a 49 question survey. This survey asks questions about the past week. It is answered on a scale of -2 to 2 and converted to 1 to 5, 1 is completely untrue and 5 is always true. The questionnaire is broken down into 7 sections when scoring: respiratory complaints, physical functioning, attendant systems and sleep, social relationships, anxiety, psychological well-being and social functioning. Once each scale score is calculated. The average score can be calculated by taking the mean of the subscales. This process of transformation produces a score between 0 and 100 with higher values indicating a better health-related quality of life according to content of the scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator Adherence - Average Hours</measure>
    <time_frame>6 weeks</time_frame>
    <description>The average number of hours ventilator was used per each day used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator Adherence - Days Used</measure>
    <time_frame>6 weeks</time_frame>
    <description>Average number of days used per week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Actigraphy</measure>
    <time_frame>Screening &amp; 6 weeks</time_frame>
    <description>Actigraphy is a method of measuring activity and sleep which is achieved by wearing a small watch-like device for an extended period of time. The data is intended to provide an objective measure of physical activity and sleep / week patterns during pre / post sleep studies and throughout the 6 weeks of home use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Room Air Sp02 Assessment Via Pulse Oximetry</measure>
    <time_frame>Screening &amp; 6 weeks</time_frame>
    <description>Oxygen saturation measurements as determined by pulse oximetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nocturnal Transcutaneous Capnography (TcC02)</measure>
    <time_frame>Screening &amp; 6 weeks</time_frame>
    <description>Nocturnal Transcutaneous Capnography is a non-invasive monitoring tool to measure ventilation over the night.
.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration, Efficiency and Quality of Sleep and Sleepiness (Derived From Sleep Study) - Duration</measure>
    <time_frame>Screening &amp; 6 weeks</time_frame>
    <description>Duration, efficiency and quality of sleepiness are measured by a number of different parameters. Total sleep time in each stage provides the average amount of time a participant was in that stage of sleep. This includes Stage 1, Stage 2, Stage 3/4, and Rapid Eye Movement (REM) sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration and Quality of Sleep and Sleepiness (Derived From Sleep Study) - Sleep Efficiency</measure>
    <time_frame>Screening &amp; 6 weeks</time_frame>
    <description>Duration, efficiency and quality of sleepiness are measured by a number of different parameters. Sleep efficiency is measured by the total time a participant is spent asleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration, Efficiency and Quality of Sleep and Sleepiness (Derived From Sleep Study)- Arousal and Awakening Indices</measure>
    <time_frame>Screening &amp; 6 weeks</time_frame>
    <description>The arousal index is measured by the average number of arousals or awakenings a participant has over an hour of sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration, Efficiency and Quality of Sleep and Sleepiness (Derived From Sleep Study)- Nocturnal O2 Saturation</measure>
    <time_frame>Screening &amp; 6 weeks</time_frame>
    <description>Measurement of overnight oxygen saturation as measured by percentage of oxygen saturation (SpO2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reaction Time (Psychomotor Vigilance Test-PVT)</measure>
    <time_frame>Screening &amp; 6 weeks</time_frame>
    <description>To measure trends of vigilance between the baseline screening assessment and the 6 week follow up visit comparing the three Arms/Groups. This measured how quickly participants reacted to visual stimulus. Reaction time is the latency at which the participant reacts to a visual stimulus &gt; 100 ms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Need for Continued Oxygen Supplementation</measure>
    <time_frame>Screening &amp; 6 weeks</time_frame>
    <description>Some users enrolled into the study required supplemental oxygen at different times during the day: at rest, during exertion and at night. The need for supplemental oxygen was compared at baseline and at 6 weeks.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Obesity Hypoventilation Syndrome</condition>
  <arm_group>
    <arm_group_label>AVAPS-AE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AVAPS-AE Mode of ventilation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Respironics OmniLab Advanced BiPAP S mode</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>OmniLab Advanced BiPAP S Mode of ventilation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Respironics OmniLab Advanced CPAP mode</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>OmniLab Advanced CPAP Mode of ventilation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AVAPS-AE Mode of Therapy</intervention_name>
    <description>AVAPS-AE mode is the experimental mode of therapy in this study that includes a combination of already cleared therapy attributes.</description>
    <arm_group_label>AVAPS-AE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Respironics OnmiLab BiPAP S mode</intervention_name>
    <description>Currently cleared Non-Invasive Ventilation (NIV) therapy modality</description>
    <arm_group_label>Respironics OmniLab Advanced BiPAP S mode</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Respironics OmniLab Advanced CPAP mode</intervention_name>
    <description>Currently cleared NIV therapy modality</description>
    <arm_group_label>Respironics OmniLab Advanced CPAP mode</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than or equal to 18 years of age; less than or equal to 70 years of age

          -  Diagnosis of Obesity Hypoventilation Syndrome via a diagnostic sleep study in the past
             3 months but have not initiated therapy

               -  BMI greater than or equal to 30 kg/m2

               -  Daytime PaCO2 greater than or equal to 45 mmHg

               -  Apnea Hypopnea index (AHI) &gt; 5

          -  Daytime pH &gt; 7.35

          -  Forced Expiratory Volume at 1 second / forced vital capacity (FEV1/FVC) &gt; 70%

        Exclusion Criteria:

          -  Acutely ill, medically complicated or who are medically stable, or as otherwise
             determined by the investigator

          -  Respiratory alkalosis (pH &gt; 7.45), per investigator discretion

          -  Emergency admissions on chronic respiratory failure

          -  Hospitalization for respiratory exacerbation &lt; 6 weeks prior to screening visit

          -  Participants in whom PAP therapy is otherwise medically contraindicated

          -  Impaired upper airway function. For example, obstruction due to infections(laryngitis,
             epiglottis), craniofacial malformations, tumors, uvulopalatopharyngoplasty, presence
             of tracheostomy, or bilateral vocal cord palsy that does not allow tolerance of
             Non-invasive positive pressure ventilation (NPPV)

          -  Facial trauma, burns, surgery or anatomical abnormalities interfering with mask fit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sairam Parthasarathy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southern Arizona VA Healthcare</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Babak Mokhlesi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona School of Medicine</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>May 23, 2011</study_first_submitted>
  <study_first_submitted_qc>June 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2011</study_first_posted>
  <results_first_submitted>January 2, 2019</results_first_submitted>
  <results_first_submitted_qc>April 25, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 26, 2019</results_first_posted>
  <last_update_submitted>April 25, 2019</last_update_submitted>
  <last_update_submitted_qc>April 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OHS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoventilation</mesh_term>
    <mesh_term>Obesity Hypoventilation Syndrome</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Screening Period</title>
          <description>All study participants that were screened and signed consent.</description>
        </group>
        <group group_id="P2">
          <title>AVAPS-AE</title>
          <description>AVAPS-AE mode is the experimental mode of therapy in this study that includes a combination of already cleared therapy attributes.</description>
        </group>
        <group group_id="P3">
          <title>Respironics OmniLab Advanced BiPAP S Mode</title>
          <description>Non-Invasive Ventilation (NIV) therapy modality in the OmniLab Advanced BiPAP.</description>
        </group>
        <group group_id="P4">
          <title>Respironics OmniLab Advanced CPAP Mode</title>
          <description>Non-Invasive Ventilation (NIV) therapy modality in the Respironics OmniLab Advanced CPAP</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Screening Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Study Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants that signed the consent form are considered for the baseline demographics</population>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>All study participants that signed the consent are included in the baseline characteristics to due the high screen failure rate and large number of participants that discontinued the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.0" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.3" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Daytime Partial Pressure of Carbon Dioxide in Arterial Blood (PaCO2)</title>
        <description>Daytime PaCO2 measurements will be assessed for all randomized patients to each mode of ventilation therapy (AVAPS-AE, bilevel PSV, CPAP) after 6 weeks.</description>
        <time_frame>Screening &amp; 6 weeks</time_frame>
        <population>6 participants withdrew from the study and therefore did not provide values at week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>AVAPS-AE</title>
            <description>AVAPS-AE Mode of ventilation
AVAPS-AE Mode of Therapy: AVAPS-AE mode is the experimental mode of therapy in this study that includes a combination of already cleared therapy attributes.</description>
          </group>
          <group group_id="O2">
            <title>Respironics OmniLab Advanced BiPAP S Mode</title>
            <description>OmniLab Advanced BiPAP S Mode of ventilation
Respironics OnmiLab BiPAP S mode: Currently cleared NIV therapy modality</description>
          </group>
          <group group_id="O3">
            <title>Respironics OmniLab Advanced CPAP Mode</title>
            <description>OmniLab Advanced CPAP Mode of ventilation
Respironics OmniLab Advanced CPAP mode: Currently cleared NIV therapy modality</description>
          </group>
        </group_list>
        <measure>
          <title>Daytime Partial Pressure of Carbon Dioxide in Arterial Blood (PaCO2)</title>
          <description>Daytime PaCO2 measurements will be assessed for all randomized patients to each mode of ventilation therapy (AVAPS-AE, bilevel PSV, CPAP) after 6 weeks.</description>
          <population>6 participants withdrew from the study and therefore did not provide values at week 6.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.1" spread="2.5"/>
                    <measurement group_id="O2" value="51.8" spread="8.0"/>
                    <measurement group_id="O3" value="50.7" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.7" spread="3.7"/>
                    <measurement group_id="O2" value="47.4" spread="8.9"/>
                    <measurement group_id="O3" value="40.8" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daytime Partial Pressure of Oxygen in Arterial Blood(Pa02)</title>
        <description>Daytime Pa02 measurements will be assessed for all randomized patients to each mode of ventilation therapy (AVAPS-AE, bilevel PSV, CPAP) after 6 weeks.</description>
        <time_frame>Screening &amp; 6 weeks</time_frame>
        <population>6 participants withdrew from the study and therefore did not provide values at week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>AVAPS-AE</title>
            <description>AVAPS-AE Mode of ventilation
AVAPS-AE Mode of Therapy: AVAPS-AE mode is the experimental mode of therapy in this study that includes a combination of already cleared therapy attributes.</description>
          </group>
          <group group_id="O2">
            <title>Respironics OmniLab Advanced BiPAP S Mode</title>
            <description>OmniLab Advanced BiPAP S Mode of ventilation
Respironics OnmiLab BiPAP S mode: Currently cleared NIV therapy modality</description>
          </group>
          <group group_id="O3">
            <title>Respironics OmniLab Advanced CPAP Mode</title>
            <description>OmniLab Advanced CPAP Mode of ventilation
Respironics OmniLab Advanced CPAP mode: Currently cleared NIV therapy modality</description>
          </group>
        </group_list>
        <measure>
          <title>Daytime Partial Pressure of Oxygen in Arterial Blood(Pa02)</title>
          <description>Daytime Pa02 measurements will be assessed for all randomized patients to each mode of ventilation therapy (AVAPS-AE, bilevel PSV, CPAP) after 6 weeks.</description>
          <population>6 participants withdrew from the study and therefore did not provide values at week 6.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.8" spread="5.8"/>
                    <measurement group_id="O2" value="56.9" spread="10.7"/>
                    <measurement group_id="O3" value="62.6" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.0" spread="4.5"/>
                    <measurement group_id="O2" value="58.7" spread="14.7"/>
                    <measurement group_id="O3" value="66.2" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apnea Hypopnea Index (AHI)</title>
        <description>The AHI is the number of apneas and hypopneas per hour of sleep. It will be evaluated during the screening sleep study and the 6 week follow up sleep study. AHI less than 5 is considered normal. For an Apnea-Hypopnea Index (or AHI) from 5 to 15 denotes mild sleep apnea. Fifteen to 30 is moderate, while a greater than 30 AHI is considered severe.</description>
        <time_frame>Screening &amp; 6 weeks</time_frame>
        <population>6 participants withdrew from the study and therefore did not provide values at week 6.
1 Participant did not have scorable data from the baseline PSG to calculate this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AVAPS-AE</title>
            <description>AVAPS-AE Mode of ventilation
AVAPS-AE Mode of Therapy: AVAPS-AE mode is the experimental mode of therapy in this study that includes a combination of already cleared therapy attributes.</description>
          </group>
          <group group_id="O2">
            <title>Respironics OmniLab Advanced BiPAP S Mode</title>
            <description>OmniLab Advanced BiPAP S Mode of ventilation
Respironics OnmiLab BiPAP S mode: Currently cleared NIV therapy modality</description>
          </group>
          <group group_id="O3">
            <title>Respironics OmniLab Advanced CPAP Mode</title>
            <description>OmniLab Advanced CPAP Mode of ventilation
Respironics OmniLab Advanced CPAP mode: Currently cleared NIV therapy modality</description>
          </group>
        </group_list>
        <measure>
          <title>Apnea Hypopnea Index (AHI)</title>
          <description>The AHI is the number of apneas and hypopneas per hour of sleep. It will be evaluated during the screening sleep study and the 6 week follow up sleep study. AHI less than 5 is considered normal. For an Apnea-Hypopnea Index (or AHI) from 5 to 15 denotes mild sleep apnea. Fifteen to 30 is moderate, while a greater than 30 AHI is considered severe.</description>
          <population>6 participants withdrew from the study and therefore did not provide values at week 6.
1 Participant did not have scorable data from the baseline PSG to calculate this measure.</population>
          <units>events per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.5" spread="37.9"/>
                    <measurement group_id="O2" value="67.7" spread="23.9"/>
                    <measurement group_id="O3" value="85.4" spread="33.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Titration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" spread="11.6"/>
                    <measurement group_id="O2" value="22.4" spread="11.1"/>
                    <measurement group_id="O3" value="30.1" spread="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" spread="11.8"/>
                    <measurement group_id="O2" value="12.4" spread="14.8"/>
                    <measurement group_id="O3" value="7.4" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Epworth Sleepiness Scale</title>
        <description>Epworth Sleepiness scale is a measure of daytime sleepiness. It is a series of 8 questions answered on a scale of 0 to 3, 0 being no chance of dozing and 3 being a high chance of dozing. The range of the scale is 0 to 24. The higher the total score, the higher the chance of falling asleep.</description>
        <time_frame>Screening &amp; 6 weeks</time_frame>
        <population>6 participants withdrew from the study and therefore did not provide values at week 6.
1 participant did not complete the ESS at the end of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>AVAPS-AE</title>
            <description>AVAPS-AE Mode of ventilation
AVAPS-AE Mode of Therapy: AVAPS-AE mode is the experimental mode of therapy in this study that includes a combination of already cleared therapy attributes.</description>
          </group>
          <group group_id="O2">
            <title>Respironics OmniLab Advanced BiPAP S Mode</title>
            <description>OmniLab Advanced BiPAP S Mode of ventilation
Respironics OnmiLab BiPAP S mode: Currently cleared NIV therapy modality</description>
          </group>
          <group group_id="O3">
            <title>Respironics OmniLab Advanced CPAP Mode</title>
            <description>OmniLab Advanced CPAP Mode of ventilation
Respironics OmniLab Advanced CPAP mode: Currently cleared NIV therapy modality</description>
          </group>
        </group_list>
        <measure>
          <title>Epworth Sleepiness Scale</title>
          <description>Epworth Sleepiness scale is a measure of daytime sleepiness. It is a series of 8 questions answered on a scale of 0 to 3, 0 being no chance of dozing and 3 being a high chance of dozing. The range of the scale is 0 to 24. The higher the total score, the higher the chance of falling asleep.</description>
          <population>6 participants withdrew from the study and therefore did not provide values at week 6.
1 participant did not complete the ESS at the end of the study.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" spread="4.8"/>
                    <measurement group_id="O2" value="12.0" spread="5.2"/>
                    <measurement group_id="O3" value="11.5" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" spread="5.8"/>
                    <measurement group_id="O2" value="8.1" spread="6.1"/>
                    <measurement group_id="O3" value="5.9" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severe Respiratory Insufficiency Questionnaire (SRIQ)</title>
        <description>The SRIQ is a 49 question survey. This survey asks questions about the past week. It is answered on a scale of -2 to 2 and converted to 1 to 5, 1 is completely untrue and 5 is always true. The questionnaire is broken down into 7 sections when scoring: respiratory complaints, physical functioning, attendant systems and sleep, social relationships, anxiety, psychological well-being and social functioning. Once each scale score is calculated. The average score can be calculated by taking the mean of the subscales. This process of transformation produces a score between 0 and 100 with higher values indicating a better health-related quality of life according to content of the scale.</description>
        <time_frame>Screening &amp; 6 weeks</time_frame>
        <population>6 participants withdrew from the study and therefore did not provide values at week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>AVAPS-AE</title>
            <description>AVAPS-AE Mode of ventilation
AVAPS-AE Mode of Therapy: AVAPS-AE mode is the experimental mode of therapy in this study that includes a combination of already cleared therapy attributes.</description>
          </group>
          <group group_id="O2">
            <title>Respironics OmniLab Advanced BiPAP S Mode</title>
            <description>OmniLab Advanced BiPAP S Mode of ventilation
Respironics OnmiLab BiPAP S mode: Currently cleared NIV therapy modality</description>
          </group>
          <group group_id="O3">
            <title>Respironics OmniLab Advanced CPAP Mode</title>
            <description>OmniLab Advanced CPAP Mode of ventilation
Respironics OmniLab Advanced CPAP mode: Currently cleared NIV therapy modality</description>
          </group>
        </group_list>
        <measure>
          <title>Severe Respiratory Insufficiency Questionnaire (SRIQ)</title>
          <description>The SRIQ is a 49 question survey. This survey asks questions about the past week. It is answered on a scale of -2 to 2 and converted to 1 to 5, 1 is completely untrue and 5 is always true. The questionnaire is broken down into 7 sections when scoring: respiratory complaints, physical functioning, attendant systems and sleep, social relationships, anxiety, psychological well-being and social functioning. Once each scale score is calculated. The average score can be calculated by taking the mean of the subscales. This process of transformation produces a score between 0 and 100 with higher values indicating a better health-related quality of life according to content of the scale.</description>
          <population>6 participants withdrew from the study and therefore did not provide values at week 6.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.0" spread="14.5"/>
                    <measurement group_id="O2" value="53.4" spread="14.5"/>
                    <measurement group_id="O3" value="60.0" spread="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.0" spread="13.5"/>
                    <measurement group_id="O2" value="64.8" spread="18.4"/>
                    <measurement group_id="O3" value="69.7" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventilator Adherence - Average Hours</title>
        <description>The average number of hours ventilator was used per each day used.</description>
        <time_frame>6 weeks</time_frame>
        <population>6 participants withdrew from the study and therefore did not provide values at week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>AVAPS-AE</title>
            <description>AVAPS-AE Mode of ventilation
AVAPS-AE Mode of Therapy: AVAPS-AE mode is the experimental mode of therapy in this study that includes a combination of already cleared therapy attributes.</description>
          </group>
          <group group_id="O2">
            <title>Respironics OmniLab Advanced BiPAP S Mode</title>
            <description>OmniLab Advanced BiPAP S Mode of ventilation
Respironics OnmiLab BiPAP S mode: Currently cleared NIV therapy modality</description>
          </group>
          <group group_id="O3">
            <title>Respironics OmniLab Advanced CPAP Mode</title>
            <description>OmniLab Advanced CPAP Mode of ventilation
Respironics OmniLab Advanced CPAP mode: Currently cleared NIV therapy modality</description>
          </group>
        </group_list>
        <measure>
          <title>Ventilator Adherence - Average Hours</title>
          <description>The average number of hours ventilator was used per each day used.</description>
          <population>6 participants withdrew from the study and therefore did not provide values at week 6.</population>
          <units>Hours per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="0.9"/>
                    <measurement group_id="O2" value="5.2" spread="1.7"/>
                    <measurement group_id="O3" value="6.6" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventilator Adherence - Days Used</title>
        <description>Average number of days used per week</description>
        <time_frame>6 weeks</time_frame>
        <population>6 participants withdrew from the study and therefore did not provide values at week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>AVAPS-AE</title>
            <description>AVAPS-AE Mode of ventilation
AVAPS-AE Mode of Therapy: AVAPS-AE mode is the experimental mode of therapy in this study that includes a combination of already cleared therapy attributes.</description>
          </group>
          <group group_id="O2">
            <title>Respironics OmniLab Advanced BiPAP S Mode</title>
            <description>OmniLab Advanced BiPAP S Mode of ventilation
Respironics OnmiLab BiPAP S mode: Currently cleared NIV therapy modality</description>
          </group>
          <group group_id="O3">
            <title>Respironics OmniLab Advanced CPAP Mode</title>
            <description>OmniLab Advanced CPAP Mode of ventilation
Respironics OmniLab Advanced CPAP mode: Currently cleared NIV therapy modality</description>
          </group>
        </group_list>
        <measure>
          <title>Ventilator Adherence - Days Used</title>
          <description>Average number of days used per week</description>
          <population>6 participants withdrew from the study and therefore did not provide values at week 6.</population>
          <units>days per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="0.9"/>
                    <measurement group_id="O2" value="5.3" spread="1.5"/>
                    <measurement group_id="O3" value="6.9" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Actigraphy</title>
        <description>Actigraphy is a method of measuring activity and sleep which is achieved by wearing a small watch-like device for an extended period of time. The data is intended to provide an objective measure of physical activity and sleep / week patterns during pre / post sleep studies and throughout the 6 weeks of home use.</description>
        <time_frame>Screening &amp; 6 weeks</time_frame>
        <population>Participants were asked to wear an actiwatch to measure actigraphy. Actigraphy was reviewed as part of the study however a detailed analysis was not conducted because the data was to variable.</population>
        <group_list>
          <group group_id="O1">
            <title>AVAPS-AE</title>
            <description>AVAPS-AE Mode of ventilation
AVAPS-AE Mode of Therapy: AVAPS-AE mode is the experimental mode of therapy in this study that includes a combination of already cleared therapy attributes.</description>
          </group>
          <group group_id="O2">
            <title>Respironics OmniLab Advanced BiPAP S Mode</title>
            <description>OmniLab Advanced BiPAP S Mode of ventilation
Respironics OnmiLab BiPAP S mode: Currently cleared NIV therapy modality</description>
          </group>
          <group group_id="O3">
            <title>Respironics OmniLab Advanced CPAP Mode</title>
            <description>OmniLab Advanced CPAP Mode of ventilation
Respironics OmniLab Advanced CPAP mode: Currently cleared NIV therapy modality</description>
          </group>
        </group_list>
        <measure>
          <title>Actigraphy</title>
          <description>Actigraphy is a method of measuring activity and sleep which is achieved by wearing a small watch-like device for an extended period of time. The data is intended to provide an objective measure of physical activity and sleep / week patterns during pre / post sleep studies and throughout the 6 weeks of home use.</description>
          <population>Participants were asked to wear an actiwatch to measure actigraphy. Actigraphy was reviewed as part of the study however a detailed analysis was not conducted because the data was to variable.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Room Air Sp02 Assessment Via Pulse Oximetry</title>
        <description>Oxygen saturation measurements as determined by pulse oximetry</description>
        <time_frame>Screening &amp; 6 weeks</time_frame>
        <population>6 participants withdrew from the study and therefore did not provide values at week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>AVAPS-AE</title>
            <description>AVAPS-AE Mode of ventilation
AVAPS-AE Mode of Therapy: AVAPS-AE mode is the experimental mode of therapy in this study that includes a combination of already cleared therapy attributes.</description>
          </group>
          <group group_id="O2">
            <title>Respironics OmniLab Advanced BiPAP S Mode</title>
            <description>OmniLab Advanced BiPAP S Mode of ventilation
Respironics OnmiLab BiPAP S mode: Currently cleared NIV therapy modality</description>
          </group>
          <group group_id="O3">
            <title>Respironics OmniLab Advanced CPAP Mode</title>
            <description>OmniLab Advanced CPAP Mode of ventilation
Respironics OmniLab Advanced CPAP mode: Currently cleared NIV therapy modality</description>
          </group>
        </group_list>
        <measure>
          <title>Room Air Sp02 Assessment Via Pulse Oximetry</title>
          <description>Oxygen saturation measurements as determined by pulse oximetry</description>
          <population>6 participants withdrew from the study and therefore did not provide values at week 6.</population>
          <units>percentage of oxygen saturation (SpO2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.5" spread="3.4"/>
                    <measurement group_id="O2" value="90.6" spread="4.1"/>
                    <measurement group_id="O3" value="92.9" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.6" spread="2.0"/>
                    <measurement group_id="O2" value="90.1" spread="7.2"/>
                    <measurement group_id="O3" value="94.1" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nocturnal Transcutaneous Capnography (TcC02)</title>
        <description>Nocturnal Transcutaneous Capnography is a non-invasive monitoring tool to measure ventilation over the night.
.</description>
        <time_frame>Screening &amp; 6 weeks</time_frame>
        <population>This measure was not a standard practice of the sleep scoring company and was not done.</population>
        <group_list>
          <group group_id="O1">
            <title>AVAPS-AE</title>
            <description>AVAPS-AE Mode of ventilation
AVAPS-AE Mode of Therapy: AVAPS-AE mode is the experimental mode of therapy in this study that includes a combination of already cleared therapy attributes.</description>
          </group>
          <group group_id="O2">
            <title>Respironics OmniLab Advanced BiPAP S Mode</title>
            <description>OmniLab Advanced BiPAP S Mode of ventilation
Respironics OnmiLab BiPAP S mode: Currently cleared NIV therapy modality</description>
          </group>
          <group group_id="O3">
            <title>Respironics OmniLab Advanced CPAP Mode</title>
            <description>OmniLab Advanced CPAP Mode of ventilation
Respironics OmniLab Advanced CPAP mode: Currently cleared NIV therapy modality</description>
          </group>
        </group_list>
        <measure>
          <title>Nocturnal Transcutaneous Capnography (TcC02)</title>
          <description>Nocturnal Transcutaneous Capnography is a non-invasive monitoring tool to measure ventilation over the night.
.</description>
          <population>This measure was not a standard practice of the sleep scoring company and was not done.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration, Efficiency and Quality of Sleep and Sleepiness (Derived From Sleep Study) - Duration</title>
        <description>Duration, efficiency and quality of sleepiness are measured by a number of different parameters. Total sleep time in each stage provides the average amount of time a participant was in that stage of sleep. This includes Stage 1, Stage 2, Stage 3/4, and Rapid Eye Movement (REM) sleep.</description>
        <time_frame>Screening &amp; 6 weeks</time_frame>
        <population>6 participants withdrew from the study and therefore did not provide values at week 6.
1 Participant did not have scorable data from the baseline PSG to calculate this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AVAPS-AE</title>
            <description>AVAPS-AE Mode of ventilation
AVAPS-AE Mode of Therapy: AVAPS-AE mode is the experimental mode of therapy in this study that includes a combination of already cleared therapy attributes.</description>
          </group>
          <group group_id="O2">
            <title>Respironics OmniLab Advanced BiPAP S Mode</title>
            <description>OmniLab Advanced BiPAP S Mode of ventilation
Respironics OnmiLab BiPAP S mode: Currently cleared NIV therapy modality</description>
          </group>
          <group group_id="O3">
            <title>Respironics OmniLab Advanced CPAP Mode</title>
            <description>OmniLab Advanced CPAP Mode of ventilation
Respironics OmniLab Advanced CPAP mode: Currently cleared NIV therapy modality</description>
          </group>
        </group_list>
        <measure>
          <title>Duration, Efficiency and Quality of Sleep and Sleepiness (Derived From Sleep Study) - Duration</title>
          <description>Duration, efficiency and quality of sleepiness are measured by a number of different parameters. Total sleep time in each stage provides the average amount of time a participant was in that stage of sleep. This includes Stage 1, Stage 2, Stage 3/4, and Rapid Eye Movement (REM) sleep.</description>
          <population>6 participants withdrew from the study and therefore did not provide values at week 6.
1 Participant did not have scorable data from the baseline PSG to calculate this measure.</population>
          <units>percentage of time spent in that stage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Sleep Time Stage 1- Screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.4" spread="19.5"/>
                    <measurement group_id="O2" value="24.6" spread="26.6"/>
                    <measurement group_id="O3" value="18.9" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Sleep Time Stage 1- 6 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="6.8"/>
                    <measurement group_id="O2" value="13.1" spread="10.3"/>
                    <measurement group_id="O3" value="10.1" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Sleep Time Stage 2- Screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8" spread="15.8"/>
                    <measurement group_id="O2" value="59.1" spread="22.4"/>
                    <measurement group_id="O3" value="64.8" spread="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Sleep Time Stage 2-6 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.2" spread="15.1"/>
                    <measurement group_id="O2" value="52.4" spread="14.3"/>
                    <measurement group_id="O3" value="53.2" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Sleep Time Stage 3/4 - Screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="13.7"/>
                    <measurement group_id="O2" value="8.1" spread="11.7"/>
                    <measurement group_id="O3" value="7.8" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Sleep Time Stagev3/4-6 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="13.2"/>
                    <measurement group_id="O2" value="14.0" spread="10.9"/>
                    <measurement group_id="O3" value="16.6" spread="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Sleep Time Stage REM- Screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" spread="7.4"/>
                    <measurement group_id="O2" value="8.2" spread="10.1"/>
                    <measurement group_id="O3" value="8.5" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Sleep Time Stage REM-6 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" spread="8.9"/>
                    <measurement group_id="O2" value="20.4" spread="9.1"/>
                    <measurement group_id="O3" value="20.1" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration and Quality of Sleep and Sleepiness (Derived From Sleep Study) - Sleep Efficiency</title>
        <description>Duration, efficiency and quality of sleepiness are measured by a number of different parameters. Sleep efficiency is measured by the total time a participant is spent asleep.</description>
        <time_frame>Screening &amp; 6 weeks</time_frame>
        <population>6 participants withdrew from the study and therefore did not provide values at week 6.
1 Participant did not have scorable data from the baseline PSG to calculate this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AVAPS-AE</title>
            <description>AVAPS-AE Mode of ventilation
AVAPS-AE Mode of Therapy: AVAPS-AE mode is the experimental mode of therapy in this study that includes a combination of already cleared therapy attributes.</description>
          </group>
          <group group_id="O2">
            <title>Respironics OmniLab Advanced BiPAP S Mode</title>
            <description>OmniLab Advanced BiPAP S Mode of ventilation
Respironics OnmiLab BiPAP S mode: Currently cleared NIV therapy modality</description>
          </group>
          <group group_id="O3">
            <title>Respironics OmniLab Advanced CPAP Mode</title>
            <description>OmniLab Advanced CPAP Mode of ventilation
Respironics OmniLab Advanced CPAP mode: Currently cleared NIV therapy modality</description>
          </group>
        </group_list>
        <measure>
          <title>Duration and Quality of Sleep and Sleepiness (Derived From Sleep Study) - Sleep Efficiency</title>
          <description>Duration, efficiency and quality of sleepiness are measured by a number of different parameters. Sleep efficiency is measured by the total time a participant is spent asleep.</description>
          <population>6 participants withdrew from the study and therefore did not provide values at week 6.
1 Participant did not have scorable data from the baseline PSG to calculate this measure.</population>
          <units>percentage of time spent in that stage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sleep Efficiency - Screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.4" spread="14.9"/>
                    <measurement group_id="O2" value="64.5" spread="14.9"/>
                    <measurement group_id="O3" value="74.6" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep Efficiency - 6 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.8" spread="8.4"/>
                    <measurement group_id="O2" value="71.4" spread="17.1"/>
                    <measurement group_id="O3" value="74.4" spread="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration, Efficiency and Quality of Sleep and Sleepiness (Derived From Sleep Study)- Arousal and Awakening Indices</title>
        <description>The arousal index is measured by the average number of arousals or awakenings a participant has over an hour of sleep.</description>
        <time_frame>Screening &amp; 6 weeks</time_frame>
        <population>6 participants withdrew from the study and therefore did not provide values at week 6.
1 Participant did not have scorable data from the baseline PSG to calculate this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AVAPS-AE</title>
            <description>AVAPS-AE Mode of ventilation
AVAPS-AE Mode of Therapy: AVAPS-AE mode is the experimental mode of therapy in this study that includes a combination of already cleared therapy attributes.</description>
          </group>
          <group group_id="O2">
            <title>Respironics OmniLab Advanced BiPAP S Mode</title>
            <description>OmniLab Advanced BiPAP S Mode of ventilation
Respironics OnmiLab BiPAP S mode: Currently cleared NIV therapy modality</description>
          </group>
          <group group_id="O3">
            <title>Respironics OmniLab Advanced CPAP Mode</title>
            <description>OmniLab Advanced CPAP Mode of ventilation
Respironics OmniLab Advanced CPAP mode: Currently cleared NIV therapy modality</description>
          </group>
        </group_list>
        <measure>
          <title>Duration, Efficiency and Quality of Sleep and Sleepiness (Derived From Sleep Study)- Arousal and Awakening Indices</title>
          <description>The arousal index is measured by the average number of arousals or awakenings a participant has over an hour of sleep.</description>
          <population>6 participants withdrew from the study and therefore did not provide values at week 6.
1 Participant did not have scorable data from the baseline PSG to calculate this measure.</population>
          <units>arousals per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.2" spread="31.2"/>
                    <measurement group_id="O2" value="66.0" spread="20.9"/>
                    <measurement group_id="O3" value="71.4" spread="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4" spread="9.3"/>
                    <measurement group_id="O2" value="23.0" spread="10.9"/>
                    <measurement group_id="O3" value="21.3" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration, Efficiency and Quality of Sleep and Sleepiness (Derived From Sleep Study)- Nocturnal O2 Saturation</title>
        <description>Measurement of overnight oxygen saturation as measured by percentage of oxygen saturation (SpO2)</description>
        <time_frame>Screening &amp; 6 weeks</time_frame>
        <population>6 participants withdrew from the study and therefore did not provide values at week 6.
1 Participant did not have scorable data from the baseline PSG to calculate this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>AVAPS-AE</title>
            <description>AVAPS-AE Mode of ventilation
AVAPS-AE Mode of Therapy: AVAPS-AE mode is the experimental mode of therapy in this study that includes a combination of already cleared therapy attributes.</description>
          </group>
          <group group_id="O2">
            <title>Respironics OmniLab Advanced BiPAP S Mode</title>
            <description>OmniLab Advanced BiPAP S Mode of ventilation
Respironics OnmiLab BiPAP S mode: Currently cleared NIV therapy modality</description>
          </group>
          <group group_id="O3">
            <title>Respironics OmniLab Advanced CPAP Mode</title>
            <description>OmniLab Advanced CPAP Mode of ventilation
Respironics OmniLab Advanced CPAP mode: Currently cleared NIV therapy modality</description>
          </group>
        </group_list>
        <measure>
          <title>Duration, Efficiency and Quality of Sleep and Sleepiness (Derived From Sleep Study)- Nocturnal O2 Saturation</title>
          <description>Measurement of overnight oxygen saturation as measured by percentage of oxygen saturation (SpO2)</description>
          <population>6 participants withdrew from the study and therefore did not provide values at week 6.
1 Participant did not have scorable data from the baseline PSG to calculate this measure.</population>
          <units>percentage of oxygen saturation (SpO2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.2" spread="6.0"/>
                    <measurement group_id="O2" value="81.6" spread="7.5"/>
                    <measurement group_id="O3" value="81.1" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.7" spread="2.5"/>
                    <measurement group_id="O2" value="93.3" spread="2.9"/>
                    <measurement group_id="O3" value="94.5" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reaction Time (Psychomotor Vigilance Test-PVT)</title>
        <description>To measure trends of vigilance between the baseline screening assessment and the 6 week follow up visit comparing the three Arms/Groups. This measured how quickly participants reacted to visual stimulus. Reaction time is the latency at which the participant reacts to a visual stimulus &gt; 100 ms.</description>
        <time_frame>Screening &amp; 6 weeks</time_frame>
        <population>participant from the AVAPS-AE Arm/Group did not complete the baseline screening PVT.
participants from the Omnilab Advanced BIPAP Arm/Group did not complete the 6 week follow up PVT.
participants from the Omnilab Advanced CPAP Arm/Group did not complete the 6 week follow up PVT.</population>
        <group_list>
          <group group_id="O1">
            <title>AVAPS-AE</title>
            <description>AVAPS-AE Mode of ventilation
AVAPS-AE Mode of Therapy: AVAPS-AE mode is the experimental mode of therapy in this study that includes a combination of already cleared therapy attributes.</description>
          </group>
          <group group_id="O2">
            <title>Respironics OmniLab Advanced BiPAP S Mode</title>
            <description>OmniLab Advanced BiPAP S Mode of ventilation
Respironics OnmiLab BiPAP S mode: Currently cleared NIV therapy modality</description>
          </group>
          <group group_id="O3">
            <title>Respironics OmniLab Advanced CPAP Mode</title>
            <description>OmniLab Advanced CPAP Mode of ventilation
Respironics OmniLab Advanced CPAP mode: Currently cleared NIV therapy modality</description>
          </group>
        </group_list>
        <measure>
          <title>Reaction Time (Psychomotor Vigilance Test-PVT)</title>
          <description>To measure trends of vigilance between the baseline screening assessment and the 6 week follow up visit comparing the three Arms/Groups. This measured how quickly participants reacted to visual stimulus. Reaction time is the latency at which the participant reacts to a visual stimulus &gt; 100 ms.</description>
          <population>participant from the AVAPS-AE Arm/Group did not complete the baseline screening PVT.
participants from the Omnilab Advanced BIPAP Arm/Group did not complete the 6 week follow up PVT.
participants from the Omnilab Advanced CPAP Arm/Group did not complete the 6 week follow up PVT.</population>
          <units>milliseconds</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3987.13" spread="8441.71"/>
                    <measurement group_id="O2" value="4752.75" spread="11435.85"/>
                    <measurement group_id="O3" value="4523.25" spread="10820.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2978.89" spread="7133.21"/>
                    <measurement group_id="O2" value="5681.83" spread="12593.01"/>
                    <measurement group_id="O3" value="6705.20" spread="13840.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Need for Continued Oxygen Supplementation</title>
        <description>Some users enrolled into the study required supplemental oxygen at different times during the day: at rest, during exertion and at night. The need for supplemental oxygen was compared at baseline and at 6 weeks.</description>
        <time_frame>Screening &amp; 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AVAPS-AE</title>
            <description>AVAPS-AE Mode of ventilation
AVAPS-AE Mode of Therapy: AVAPS-AE mode is the experimental mode of therapy in this study that includes a combination of already cleared therapy attributes.</description>
          </group>
          <group group_id="O2">
            <title>Respironics OmniLab Advanced BiPAP S Mode</title>
            <description>OmniLab Advanced BiPAP S Mode of ventilation
Respironics OnmiLab BiPAP S mode: Currently cleared NIV therapy modality</description>
          </group>
          <group group_id="O3">
            <title>Respironics OmniLab Advanced CPAP Mode</title>
            <description>OmniLab Advanced CPAP Mode of ventilation
Respironics OmniLab Advanced CPAP mode: Currently cleared NIV therapy modality</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Need for Continued Oxygen Supplementation</title>
          <description>Some users enrolled into the study required supplemental oxygen at different times during the day: at rest, during exertion and at night. The need for supplemental oxygen was compared at baseline and at 6 weeks.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Rest- Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Rest-6 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Sleep- Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Sleep- 6 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Exertion- Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Exertion- 6 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All Adverse Events experienced over 6 weeks were collected.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AVAPS-AE</title>
          <description>AVAPS-AE Mode of ventilation
AVAPS-AE Mode of Therapy: AVAPS-AE mode is the experimental mode of therapy in this study that includes a combination of already cleared therapy attributes.</description>
        </group>
        <group group_id="E2">
          <title>Respironics OmniLab Advanced BiPAP S Mode</title>
          <description>OmniLab Advanced BiPAP S Mode of ventilation
Respironics OnmiLab BiPAP S mode: Currently cleared NIV therapy modality</description>
        </group>
        <group group_id="E3">
          <title>Respironics OmniLab Advanced CPAP Mode</title>
          <description>OmniLab Advanced CPAP Mode of ventilation
Respironics OmniLab Advanced CPAP mode: Currently cleared NIV therapy modality</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Fournier's Gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeff Jasko</name_or_title>
      <organization>Philips</organization>
      <phone>412-542-3651</phone>
      <email>jeff.jasko@philips.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

